Priced for one buyer, wanted by many: management describes new sources of demand converging on the same thing it already
The model's full reasoning — Q1 2017 call → NOWe need answer YES/NO based on transcript. Need identify if management describes demand for same thing company already makes coming from more than one direction, widening recently, and managing convergence with numbers lagging. Let's parse transcript. Company Ionis Pharmaceuticals. They have SPINRAZA (approved drug for SMA) with sales. Also volanesorsen (not yet approved, filing later). IONIS-TTRRx (Phase III data imminent). They have pipeline. The question asks about "same thing the company already makes or does" - existing offering. Could be SPINRAZA? Demand from multiple geographies? They mention U.S. launch, EU approval pending, Canada/Japan expected. But is that widening? They describe SPINRAZA sales in U.S., positive CHMP for EU, filings in other countries. But is that "recently widened" with real transactions? EU not yet approved, so not actual. U.S. launch expanding sites. But that's same product, same use, geographic expansion? The demand base widening geographically? But EU approval pending, not yet. Canada/Japan expected this year. So not actual transactions yet. Also they mention "patients with Type 2 and Type 3 SMA" - Biogen seeking coverage approvals for those types. That could be widening of patient population? But SPINRAZA approved for all types? Actually label broad? They mention "majority of patients treated have been Type 1, Biogen continues to seek coverage approvals for patients with Type 2 and Type 3 SMA." That is a widening of demand from different patient types? But is that "same thing company already makes"? Yes, SPINRAZA. But is it "recently widened" and "real"? They are seeking coverage approvals, not yet fully. Some patients covered without stated coverage. But management describes it as ongoing. However, the question asks "demand for the same thing the company already makes or does is now coming from more than one direction at once" - e.g., different uses, applications, geographies. Here, SPINRAZA is same drug, but demand from different SMA types? That's not really different "directions" - it's same disease, same drug, just broader patient population within same indication. Also geographic expansion is prospective. Another possibility: The company's technology platform? They have multiple partnerships. But "same thing" - antisense technology? They license to partners.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| LINC | Lincoln Educational Services Corporation | Q1 2024 | 2024-05-06 | B+ |
| WEC | WEC Energy Group, Inc. | Q1 2024 | 2024-05-01 | A |
| OPAD | Offerpad Solutions Inc. | Q3 2023 | 2023-11-01 | C |
| PFIE | Profire Energy, Inc. | Q1 2023 | 2023-05-13 | B |
| PRPH | ProPhase Labs, Inc. | Q1 2023 | 2023-05-11 | F |
| EVGO | EVgo, Inc. | Q2 2022 | 2022-08-09 | C+ |
| OGI | OrganiGram Holdings Inc. | Q3 2022 | 2022-07-14 | B+ |
| ADSE | ADS-TEC Energy PLC | Q4 2021 | 2022-04-28 | D |
| CNS | Cohen & Steers, Inc. | Q2 2017 | 2017-07-20 | B |
| GOGO | Gogo Inc. | Q1 2016 | 2016-05-06 | C+ |
| WK | Workiva Inc. | Q4 2015 | 2016-03-01 | B |
| HPP | Hudson Pacific Properties, Inc. | Q4 2015 | 2016-02-25 | C |
LINC · Q1 2024 → YESThe question is about whether management describes demand for the same thing the company already makes coming from more than one direction at once, with specific criteria. YES Management describes the core offering—curriculum and training capabilities already in place—as now being applied in a new direction: B2B corporate upskilling contracts (e.g., the CMC agreement) alongside campus-based student programs. They explicitly state they are pursuing additional employer contracts and expanding corporate partnerships, with the new 5-year, $6 million CMC deal representing real, recent revenue that contributed nothing to the reported quarter and is still ramping up through site setup and staffing. This meets all three criteria as a single coherent development.
OPAD · Q3 2023 → YESThe question is about whether management describes demand for the same thing the company already makes coming from more than one direction at once, with specific criteria. YES The transcript shows management describing demand for renovations (already part of their core iBuyer operations) now coming from multiple directions: their own inventory, third-party B2B clients (nearly 50 clients, 127% increase in closed projects), and soon homeowners via Rental Captain.
PFIE · Q1 2023 → YESThe question is about whether management describes demand for the same thing the company already makes coming from more than one direction at once, with the demand base widening recently, and manageme...